Decline in sales of Lipidil, a treatment for hyperlipidemia
First written in FY2019-Q2. 5 of 7 entries say "Restated". Latest entry: FY2021.
The whole theme swung hardest in 2018: 24 of 73 companies on the "Worse" side.
2 other companies' latest entry also says "Dropped".
- FY2021DroppedAnnual report
「In pharmaceuticals and medical devices, revenue declined due to lower sales of ARTZ, a joint function improvement agent, and KLEENAFIN, a treatment for onychomycosis, as well as lower overseas sales.」
Lipidil, which had been cited as a factor behind lower pharmaceutical-business revenue through the previous fiscal year, was excluded from the list of major factors behind lower revenue in the current fiscal year. - FY2020-Q3RestatedAnnual report
「In pharmaceuticals and medical devices, sales of Krenafin, a treatment for toenail onychomycosis, and Seprafilm, an absorbable adhesion barrier, were broadly in line with the previous year, but revenue declined due to lower sales of Alz, a joint-function improvement drug, and Lipidil, a treatment for hyperlipidemia, among other factors.」
The decline in Lipidil sales continued to be cited from the previous quarter as one of the factors behind lower pharmaceutical-business revenue. - FY2020-Q2RestatedAnnual report
「Revenue declined because sales of Lipidil, a treatment for hyperlipidemia, fell due to the impact of generic drugs, while overseas sales also declined.」
The decline in Lipidil sales continues to be cited in the current cumulative second quarter as being attributable to the impact of generic drugs. - FY2020-Q1RestatedAnnual report
「Revenue declined because sales of Lipidil, a treatment for hyperlipidemia, fell due to the impact of generic drugs, while overseas sales also declined.」
The decline in Lipidil sales continues to be cited in the current first quarter as being attributable to the impact of generic drugs. - FY2019RestatedAnnual report
「Revenue declined due to lower sales of Lipidil, a treatment for hyperlipidemia, among other factors.」
The decline in Lipidil sales continued to be cited as one of the factors behind lower annual pharmaceutical-business revenue. - FY2019-Q3RestatedAnnual report
「Sales of Crenafin, a treatment for onychomycosis, increased, but sales declined due to lower sales of Alz, a joint-function improvement agent, and Lipidil, a treatment for hyperlipidemia, among other factors.」
The decline in Lipidil sales continues to be cited as one of the factors behind lower pharmaceutical-business revenue, which was affected by drug price revisions and measures promoting the use of generic drugs. - FY2019-Q2First statedAnnual report
「Sales of Crenafin, a treatment for onychomycosis, increased, but sales declined due to lower sales of Alz, a joint-function improvement agent, and Lipidil, a treatment for hyperlipidemia, among other factors.」
The decline in Lipidil sales was explicitly identified for the first time as one of the factors behind lower pharmaceutical-business revenue, which was affected by drug price revisions and measures promoting the use of generic drugs.